CHE.NYSEChemed CORP
DEF 14A: Chemed Corporation Outlines Executive Compensation and Governance Proposals in Proxy Statement
Sentiment:
Proxy Statement
Chemed Corporation's proxy statement details proposals for the upcoming annual meeting, including director elections, auditor ratification, executive compensation, and a shareholder proposal on golden parachutes.
Summary
- Chemed Corporation has released its proxy statement for the annual meeting of stockholders to be held on May 20, 2024.
- The proxy statement includes proposals for the election of directors, ratification of the selection of independent accountants, an advisory vote on executive compensation, and a stockholder proposal regarding termination pay.
- Stockholders of record as of March 25, 2024, are entitled to vote at the Annual Meeting.
- The Board of Directors recommends voting FOR the election of each of the Board's nominees, FOR the ratification of the selection of PricewaterhouseCoopers LLP as independent accountants, FOR the advisory vote on executive compensation, and AGAINST the stockholder proposal regarding termination pay.
- The proxy statement details the compensation of the company's named executive officers, including base salary, annual cash incentive compensation, and long-term incentive compensation.
- The company's executive compensation program is designed to align executives' interests with those of stockholders by rewarding long-term growth, paying for performance, and attracting and retaining senior executives.
- The proxy statement also includes information on corporate governance, including the composition and responsibilities of the Board's committees, director independence, and risk oversight.
- The company has a clawback policy in place to recover erroneously awarded compensation.
- The company's policy prohibits officers and directors from hedging shares of Capital Stock.
- The company's compensation committee has adopted a policy to seek stockholder approval of new severance arrangements.
Sentiment
Score: 7
Explanation: The document is a standard proxy statement, which is generally neutral in tone. The Board's recommendations are positive for the company's proposals, but there is also a dissenting shareholder proposal. Overall, the sentiment is slightly positive due to the Board's confidence in its compensation and governance practices.
Positives
- The company's executive compensation program is designed to align executives' interests with those of stockholders.
- The company has a clawback policy in place to recover erroneously awarded compensation.
- The company's policy prohibits officers and directors from hedging shares of Capital Stock.
- The company's compensation committee has adopted a policy to seek stockholder approval of new severance arrangements.
- Stockholders voted 77.22% in favor of executive compensation in 2023.
Negatives
- The stockholder proposal regarding termination pay received 48% support at the 2023 Chemed annual meeting, indicating some stockholder dissatisfaction with the company's severance practices.
Risks
- The company faces risks related to regulatory changes, material litigation, cybersecurity, and economic conditions.
- The company's compensation policies and practices could create risks that are reasonably likely to have a material adverse effect on the company if not properly managed.
Future Outlook
The proxy statement includes proposals for the 2025 Annual Meeting of Stockholders, including deadlines for stockholder proposals to be included in the company's proxy statement and for other business to be brought before the meeting.
Management Comments
- The Board believes that our current executive compensation program directly links executive compensation to our financial performance and aligns the interests of our executive officers with those of our stockholders.
- Our Board also believes that our executive compensation program provides our executive officers with a balanced compensation package that includes a reasonable base salary along with annual and long-term incentive compensation plans that are based on the Company's financial performance.
Industry Context
The proxy statement provides context for Chemed's executive compensation program by comparing it to those of its peer group companies and discussing the factors that the Compensation Committee considers when making compensation decisions.
Comparison to Industry Standards
- The Compensation Committee reviews the peer group used to benchmark executive compensation.
- Based on changes to our previous Peer Group and increases in the Company's annual revenues and market capitalization, the Compensation Committee selected a new Peer Group.
- The new Peer Group, adopted in early 2020 and reviewed in 2023, is as follows: ABM Industries, Inc., Pediatrix Medical Group, Acadia Healthcare Co., Inc. (formerly MEDNAX, INC.), Amedisys, Inc., RadNet, Inc., Brookdale Senior Living, Inc., Rollins, Inc., Clean Harbors, Inc., Select Medical Holdings Corp., Comfort Systems USA, Inc., Stericycle, Inc., Team, Inc., Healthcare Services Group, Inc., Tetra Tech, Inc., National Healthcare Corp., The Ensign Group, Inc.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Adoption of Executive Officer Cash Severance Policy | The Compensation Committee has adopted a policy to seek stockholder approval of new severance arrangements that provide for Cash Severance Payments exceeding 2.99 times the sum of the Base Salary and the Target Bonus of the Executive Officer. | February 16, 2024 | This policy is intended to address stockholder concerns about excessive severance payouts and to strike a balance between due regard for stockholders' interests and the company's need to attract and retain talent. |
Related Party Transactions
- A son of Mr. McNamara, the Company's Chief Executive Officer, began employment with Chemed in November of 2018, after previously serving as Director of Innovation and Development at VITAS. His salary for 2023 plus his bonus for 2023 paid in 2024 was $394,821. He also received stock options and performance stock units commensurate with his level of responsibilities. His compensation package was established by the Company in accordance with our employment and compensation practices applicable to employees with equivalent qualifications and responsibilities and holding similar positions.
Stakeholder Impact
- The proxy statement provides information to stockholders to enable them to make informed decisions about voting on the proposals.
- The executive compensation program is designed to align the interests of executives with those of stockholders.
- The company's corporate governance practices are intended to protect the interests of all stakeholders.
Next Steps
- Stockholders are urged to vote on the proposals outlined in the proxy statement.
- The Annual Meeting of Stockholders will be held on May 20, 2024.
Key Dates
| Date | Description |
|---|---|
| 1971 | PricewaterhouseCoopers LLP has acted as independent accountants for the Company and its consolidated subsidiaries since this date. |
| 2000 | The Audit Committee developed a charter for the Committee, which was approved by the full Board of Directors on May 15, 2000. |
| 2007 | In February 2007, the Audit Committee adopted a written policy and set of procedures for reviewing transactions between the Company and related persons. |
| 2008 | On May 3, 2008, Mr. McNamara entered into a two-year employment agreement, which automatically renews every May 3 beginning May 3, 2010 for a new two-year term unless either party provides 30 days prior written notice of non-renewal. |
| 2010 | The Company has four Stock Incentive Plans under which stock option awards to purchase shares of Capital Stock, performance share units, and awards of restricted and fully vested stock may be granted for a period of up to ten years to key employees: the 2010 Incentive Plan, 2015 Incentive Plan, the 2018 Incentive Plan and the 2022 Incentive Plan. |
| 2013 | Beginning in 2013, in the event of a change in control of the Company, all stock option and stock award incentives are subject to a double trigger vesting, requiring employment termination coupled with a change in control. |
| 2015 | No grants of time-based restricted stock awards have been granted since May 2015, nor are any contemplated. |
| 2018 | This policy was revised in August 2018. Previously, if payments under the Senior Executive Severance Policy were subject to the excise taxes imposed by Section 409A of the Code, participants would be entitled to gross-up payments. |
| 2018 | A son of Mr. McNamara, the Company's Chief Executive Officer, began employment with Chemed in November of 2018, after previously serving as Director of Innovation and Development at VITAS. |
| 2019 | Beginning in 2019, the Compensation Committee began granting stock option awards on the day of the release of the Company's third quarter earnings results. |
| 2020 | Based on changes to our previous Peer Group and increases in the Company's annual revenues and market capitalization, the Compensation Committee selected a new Peer Group. The new Peer Group, adopted in early 2020 and reviewed in 2023. |
| 2022 | Due to industry-wide disruption in hospice caused by the COVID-19 pandemic that materially affected VITAS ability to grow its earnings, and thus the Company's ability to achieve growth targets for certain previously granted PSUs, in February of 2022 the Compensation Committee approved a one-time special cash incentive for certain members of the Company's management. |
| 2023 | All ten nominees named below are current directors standing for re-election, all of whom were elected at the Annual Meeting of Stockholders held on May 15, 2023. |
| 2023 | In February 2023, the Compensation Committee granted performance-based share units under the 2018 Plan. |
| 2023 | Effective May 1, 2023, the Compensation Committee recommended base salary increases of 7.0% to Mr. McNamara, Mr. Williams, Mr. Witzeman, and Mr. Lee. |
| 2023 | The Compensation Committee recommended Mr. Westfall receive a base salary increase of 6.0% effective June 1, 2023. |
| 2023 | At the end of 2023, Mr. Williams transitioned from the Company's Chief Financial Officer to an employee advisor to the Chief Executive Officer. |
| 2024 | The Annual Meeting of Stockholders of Chemed Corporation will be held at the Queen City Club, 331 East Fourth Street, Cincinnati, Ohio on May 20, 2024, at 11:00 a.m. Eastern Time. |
| 2024 | The approximate date on which this Proxy Statement and the enclosed proxy card are first being given or sent to stockholders is April 8, 2024. |
| 2024 | In 2023 the Company timely adopted a Recovery Policy for Erroneously Awarded Compensation that conforms with the NYSE requirements, which is included as Exhibit 97.1 to the Company's 10-K for 2023. |
| 2024 | The Committee shall administer the Policy. Subject to the provisions of the Policy and applicable law, the Committee shall have the sole authority to make any determination and take any other action that it in good faith deems necessary or advisable for the administration of the Policy, including, without limitation, determining the present value of any amounts payable over time. |
| 2025 | To comply with the universal proxy rules and the Company's by-laws, stockholders who intend to solicit proxies in support of director nominees other than the Company's nominees must provide notice that sets forth the information required by Rule 14a-19 under the Exchange Act no later than March 16, 2025. |
Keywords
executive compensation, corporate governance, proxy statement, annual meeting, directors, stockholders, severance, audit committee, compensation committee, risk oversight
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.